Access to treatment for hepatitis C virus infection: time to put patients first

The Lancet Infectious Diseases

Volumn 16, Issue 9, 2016, Pages e196-e201

  Edlin, Brian R ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NATIONAL DEVELOPMENT AND RESEARCH INSTITUTES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

ANTIVIRAL THERAPY; CONSENSUS; DRUG COST; DRUG LEGISLATION; EPIDEMIC; HEALTH CARE ACCESS; HEALTH CARE COST; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; DRUG EFFECTS; ECONOMICS; HEALTH CARE POLICY; HEPACIVIRUS; LIVER CIRRHOSIS; PUBLIC HEALTH;

ANTIVIRAL AGENTS; HEALTH POLICY; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; PUBLIC HEALTH;

EID: 84979561662     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(16)30005-6     Document Type: Review

References (78)

1. 1 American Association for the Study of Liver Diseases, Infectious Diseases Society of America. Hepatitis C guidance: recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org/sites/default/files/full_report.pdf, March 12, 2014 (accessed September, 2015).
2. 2 Ly, KN, Xing, J, Klevens, RM, Jiles, RB, Ward, JW, Holmberg, SD, The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 156 (2012), 271–278.
3. 3 Colvin, H, Mitchell, AE, (eds.) Hepatitis and liver cancer: a national strategy for prevention and control of hepatitis B and C, 2010, National Academies Press, Washington, DC.
4. 4 Smith-Palmer, J, Cerri, K, Valentine, W, Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits. BMC Infect Dis, 15, 2015, 19.
5. 5 Edlin, BR, Winkelstein, ER, Can hepatitis C be eradicated in the United States?. Antiviral Res 110 (2014), 79–93.
6. 6 Institute of Medicine. A national strategy for the elimination of hepatitis B and C. http://iom.nationalacademies.org/activities/publichealth/nationalstrategyfortheeliminationofhepatitisbandc.aspx (accessed Jan 26, 2016).
7. 7 United Healthcare. Prior Authorization/Medical Necessity: Harvoni (sofosbuvir/ledipasvir), 2014, United Healthcare, Minneapolis, MN.
8. 8 Anthem. Authorization: Harvoni (sofosbuvir/ledipasvir). https://www.anthem.com/provider/noapplication/f0/s0/t0/pw_e225443.pdf (accessed Feb 18, 2015).
9. 9 Barua, S, Greenwald, R, Grebely, J, Dore, GJ, Swan, T, Taylor, LE, Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Ann Intern Med 163 (2015), 215–223.
10. 10 Canary, LA, Klevens, RM, Holmberg, SD, Limited access to new hepatitis C virus treatment under state Medicaid programs. Ann Intern Med 163 (2015), 226–228.
11. 11 Klevens M, Huang X, Yeo AE, Odeh M, Pesano RL, Ward JW. The burden of liver disease among persons with hepatitis C in the United States. Conference on Retroviruses and Opportunistic Infections; San Francisco, CA, USA; Feb 23–26, 2015. Abstract 145.
12. 12 Gilead Sciences. Gilead Sciences Announces Second Quarter 2015 Financial Results. http://www.gilead.com/news/press-releases/2015/7/gilead-sciences-announces-second-quarter-2015-financial-results, July 28, 2015 (accessed June 24, 2016).
13. 13 van de Ven, N, Fortunak, J, Simmons, B, et al. Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus. Hepatology 61 (2015), 1174–1182.
14. 14 Edlin, BR, Seal, KH, Lorvick, J, et al. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?. N Engl J Med 345 (2001), 211–214.
15. 15 National Institutes of Health. National Institutes of Health consensus development conference statement: management of hepatitis C: 2002—June 10–12, 2002. Hepatology 36:5 suppl 1 (2002), S3–20.
16. 16 Dienstag, JL, McHutchison, JG, American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology 130 (2006), 225–230.
17. 17 Yee, HS, Chang, MF, Pocha, C, et al. Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. Am J Gastroenterol 107 (2012), 669–689.
18. 18 Chahal, HS, Marseille, EA, Tice, JA, et al. Cost-effectiveness of early treatment of hepatitis C virus genotype 1 by stage of liver fibrosis in a US treatment-naive population. JAMA Intern Med 176 (2016), 65–73.
19. 19 Pear R. New York Times Dec 23, 2014: A19.
20. 20 US Department of Health and Human Services. Patient Protection and Affordable Care Act: HHS Notice of Benefit and Payment Parameters for 2016: section III.F.2.e. prohibition on discrimination. http://federalregister.gov/a/2015-03751, Feb 27, 2015 (accessed March 6, 2015).
21. 21 Toubman, SV, Hatcher, KN, Garten, SL, Gonsalves, G, Kapczynski, A, Miller, A, for the New Haven Legal Assistance Association. Letter to Commissioner Roderick Bremby re access to medications to treat and cure hepatitis C. http://www.natap.org/2015/HCV/Sovaldi.Advocates.Letter.to.DSS.Final.Signed.2.3.15.pdf, Feb 3, 2015 (accessed Oct 30, 2015).
22. 22 Nisen, M, Merck throws a wrench in drug pricing. http://www.bloomberg.com/gadfly/articles/2016-01-29/merck-zepatier-hepatitis-c-drug-price-could-be-a-game-changer, Jan 29, 2016 (accessed Feb 26, 2016).
23. 23 Stephan, J, Peters, R, Mutual forbearance among multimarket firms: a behavioral approach to tacit cooperation. J Manage Organ 19 (2013), 115–133.
24. 24 Rockoff, JD, Stynes, T, Gilead Sciences down on discounting news: drug maker says it could increase discounts to average of 46% this year, up from 22% in 2014. http://www.wsj.com/articles/gilead-sciences-down-on-discounting-news-1423070093, Feb 4, 2015 (accessed Oct 30, 2015).
25. 25 Edlin, BR, Perspective: test and treat this silent killer. Nature 474 (2011), S18–S19.
26. 26 Lo Re, V, Gowda, C, Urick, PN, et al. Incidence and determinants of denial of DAA treatment for chronic HCV infection by insurance type during the first 6 months of the modern HCV treatment era. Hepatology, 62(suppl), 2015, 1382A.
27. 27 Ollendorf, DA, Tice, JA, Pearson, SD, The comparative clinical effectiveness and value of simeprevir and sofosbuvir for chronic hepatitis C virus infection. JAMA Intern Med 174 (2014), 1170–1171.
28. 28 Brennan, T, Shrank, W, New expensive treatments for hepatitis C infection. JAMA 312 (2014), 593–594.
29. 29 Smith, BD, Morgan, RL, Beckett, GA, et al., for the Centers for Disease Control and Prevention. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965. MMWR Recomm Rep 61 (2012), 1–32.
30. 30 Moyer, VA, for the US Preventive Services Task Force. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 159 (2013), 349–357.
31. 31 Yehia, BR, Schranz, AJ, Umscheid, CA, Lo Re, V 3rd, The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis. PLoS One, 9, 2014, e101554.
32. 32 Chhatwal, J, Kanwal, F, Roberts, MS, Dunn, MA, Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med 162 (2015), 397–406.
33. 33 Ghany, MG, The ongoing debate of who to treat for chronic hepatitis C virus. JAMA Intern Med 175 (2015), 169–170.
34. 34 US Senate Committee on Finance. The price of Sovaldi and its impact on the U.S. health care system. http://www.finance.senate.gov/download/the-price-of-sovaldi-and-its-impact-on-the-us-health-care-system-full-report, Dec 1, 2015 (accessed Feb 26, 2016).
35. 35 Bach PB, Saltz LB, Wittes RE. New York Times Oct 15, 2012: A25.
36. 36 Pollack A. New York Times Nov 9, 2012: B3.
37. 37 Pollack A. New York Times Sept 22, 2015: B3.
38. 38 Rockoff, JD, Turing to cut price of drug Daraprim after increase sparks outcry. http://www.wsj.com/articles/turing-to-cut-price-of-drug-daraprim-after-increase-sparks-outcry-1442970732, Sept 22, 2015 (accessed Oct 30, 2015).
39. 39 Love, J, Nonvoluntary use of patents for drugs to treat the hepatitis C virus in the United States: mechanisms available to the Federal Government, state governments and private actors. http://keionline.org/node/2058, July 18, 2014 (accessed Feb 16, 2015).
40. 40 Weissman, R, Testimony before the U.S. Senate hearing on hepatitis C in veterans, December 3, 2014. http://www.veterans.senate.gov/hearings/hepatitis-c-in-veterans, Dec 3, 2014 (accessed Oct 30, 2015).
41. 41 WHO. Constitution of the World Health Organization, 1946, World Health Organization, Geneva.
42. 42 United Nations General Assembly. Universal Declaration of Human Rights, 1948, United Nations General Assembly, Geneva.
43. 43 United Nations General Assembly. International Covenant on Economic, Social, and Cultural Rights, 1966, United Nations General Assembly, Geneva.
44. 44 United Nations Economic and Social Council. The right to the highest attainable standard of health, general comment no. 14. E/C.12/2000/4, 2000, Office of the United Nations High Commissioner for Human Rights, Geneva.
45. 45 Gruskin, S, Mills, EJ, Tarantola, D, History, principles, and practice of health and human rights. Lancet 370 (2007), 449–455.
46. 46 Balasubramaniam, K, Access to essential medicines as a human right. http://www.politicsofmedicines.org/articles/access-to-essential-medicines-as-a-human-right (accessed Sept 18, 2015).
47. 47 Reichman, JH, Comment: compulsory licensing of patented pharmaceutical inventions: evaluating the options. J Law Med Ethics 37 (2009), 247–263.
48. 48 Love, JP, KEI RN 2007:2 Recent examples of the use of compulsory licenses on patents. http://keionline.org/content/view/41/1 (accessed Jan 22, 2015).
49. 49 Beall, R, Kuhn, R, Trends in compulsory licensing of pharmaceuticals since the Doha Declaration: a database analysis. PLoS Med, 9, 2012, e1001154.
50. 50 Quiñones-Rivera, A, The untold story of how high-quality and low-cost drugs were incorporated into PEPFAR. Ann Forum Collab HIV Res 15 (2013), 1–8.
51. 51 Sanders, SB, Letter to Veterans Affairs Secretary Robert McDonald. http://www.sanders.senate.gov/download/051215-letter/?inline=file, May 12, 2015 (accessed May 27, 2015).
52. 52 Silverman, E, Gilead patent for its Sovaldi hep C drug is rejected by Chinese authorities. http://blogs.wsj.com/pharmalot/2015/06/19/gilead-patent-for-its-sovaldi-hep-c-drug-is-rejected-by-chinese-authorities/, June 19, 2015 (accessed July 25, 2015).
53. 53 Einhorn, B, How India's patent office destroyed Gilead's global game plan. http://www.businessweek.com/articles/2015-01-15/how-indias-patent-office-destroyed-gileads-global-game-plan, Jan 15, 2015 (accessed July 25, 2015).
54. 54 Defretin, A, Hepatitis C: Doctors of the World—Médecins du Monde opposes sofosbuvir patent in Europe. http://old.medecinsdumonde.org/gb/Press/Hepatitis-C-Doctors-of-the-World-Medecins-du-Monde-opposes-sofosbuvir-patent-in-Europe, Feb 10, 2015 (accessed June 24, 2016).
55. 55 Initiative for Medicines, Access and Knowledge. Patent challenges in five countries dispute validity of Gilead's claims to hepatitis C drug patents that block treatment for up to 59 million people. http://www.prnewswire.com/news-releases/patent-challenges-in-five-countries-dispute-validity-of-gileads-claims-to-hep-c-drug-patents-that-block-treatment-for-up-to-59-million-people-300086132.html, May 20, 2015 (accessed July 25, 2015).
56. 56 Labban, M, As Gilead's HCV patents come under threat across the world should Pharma be worried?. http://blog.ihs.com/as-gilead%E2%80%99s-hcv-patents-come-under-threat-across-the-world-should-pharma-be-worried, June 26, 2015 (accessed July 25, 2015).
57. 57 Médecins Sans Frontières Access Campaign. MSF launches online resource for challenging unwarranted drug patents. https://www.msfaccess.org/resources/press-releases/1911, Oct 2, 2012 (accessed July 26, 2015).
58. 58 Barton, JH, Emanuel, EJ, The patents-based pharmaceutical development process: rationale, problems, and potential reforms. JAMA 294 (2005), 2075–2082.
59. 59 Nathan, C, Aligning pharmaceutical innovation with medical need. Nat Med 13 (2007), 304–308.
60. 60 DiJulio, B, Firth, J, Brodie, M, Kaiser health tracking poll: August 2015. http://kff.org/health-costs/poll-finding/kaiser-health-tracking-poll-august-2015/, 2015 (accessed Oct 30, 2015).
61. 61 Healy P, Sanger-Katz M. New York Times Sept 23, 2015: A13.
62. 62 Mahon, N, Presidential Advisory Council on HIVIAIDS. Letter to Secretary Sylvia Burwell on hepatitis C treatment access. https://www.aids.gov/federal-resources/pacha/meetings/2015/hcv-letter-from-nancy-mahon.pdf, June 9, 2015 (accessed Oct 30, 2015).
63. 63 Gordon, DJ, Betlach, TJ, National Association of Medicaid Directors. Letter to Congress on hepatitis C treatment challenges. http://medicaiddirectors.org/node/1083, Oct 28, 2014 (accessed Oct 30, 2015).
64. 64 Trooskin, SB, Reynolds, H, Kostman, JR, Access to costly new hepatitis C drugs: medicine, money, and advocacy. Clin Infect Dis 61 (2015), 1825–1830.
65. 65 Conti, RM, Rosenthal, MB, Pharmaceutical policy reform—balancing affordability with incentives for innovation. N Engl J Med 374 (2016), 703–706.
66. 66 Connecticut Department of Social Services Patient Assistance Program. July 1, 2015 changes to the Connecticut Medicaid preferred drug list (PDL). In: Provider Bulletin 2015-41, 2015, Connecticut Department of Social Services, Hartford CT.
67. 67 Lynch, TG, McCarthy, MF, Memorandum: hepatitis C virus funding and prioritization status update. http://www.hepatitis.va.gov/pdf/choice-prioritization-update.pdf, Feb 24, 2016 (accessed Feb 26, 2016).
68. 68 DeBoy, AM, Assuring Medicaid beneficiaries access to hepatitis C (HCV) drugs. Medicaid. https://www.medicaid.gov/Medicaid-CHIP-Program-Information/By-Topics/Benefits/Prescription-Drugs/Downloads/Rx-Releases/State-Releases/state-rel-172.pdf, Nov 5, 2015 (accessed Nov 5, 2015).
69. 69 Ellison, SF, Wolfram, C, Coordinating on lower prices: pharmaceutical pricing under political pressure. Rand J Econ 37 (2006), 324–340.
70. 70 Frakt A. New York Times Jan 18, 2016: A3.
71. 71 Stout, C, Letter to Community Partners, July 1, 2015, Gilead Sciences, Inc., Foster City, CA.
72. 72 Silverman, E, Gilead limits enrollment in its hep C patient program to pressure insurers. http://blogs.wsj.com/pharmalot/2015/07/16/gilead-limits-enrollment-in-its-hep-c-patient-program-to-pressure-insurers/, July 16, 2015 (accessed July 25, 2015).
73. 73 Hunt, P, Report of the Special Rapporteur on the right of everyone to the enjoyment of the highest attainable standard of physical and mental health. http://www.who.int/medicines/areas/human_rights/A63_263.pdf, Aug 11, 2008 (accessed March 13, 2015).
74. 74 Lee, JY, Hunt, P, Human rights responsibilities of pharmaceutical companies in relation to access to medicines. J Law Med Ethics 40 (2012), 220–233.
75. 75 Forman, L, Kohler, JC, Access to medicines as a human right: implications for pharmaceutical industry responsibility, 2012, University of Toronto Press, Toronto, ON.
76. 76 Hogerzeil, HV, Big Pharma and social responsibility—the access to medicine index. N Engl J Med 369 (2013), 896–899.
77. 77 National Viral Hepatitis Roundtable. Letter to Health and Human Services Secretary Sylvia Mathews Burwell. http://nvhr.org/sites/default/files/docs/Secretary%20Burwell%2009_10_14.pdf, Sept 10, 2014 (accessed Feb 16, 2015).
78. 78 Zibbell, JE, Iqbal, K, Patel, RC, et al. Increases in hepatitis C virus infection related to injection drug use among persons aged ≤30 years—Kentucky, Tennessee, Virginia, and West Virginia, 2006–2012. MMWR Morb Mortal Wkly Rep 64 (2015), 453–458.